Patent ID: 8546077
Filing Date: 2013-10-01
Classification: A61K,A61P,C12Q,G01N

Abstract:
1. A method for determining whether a test compound is useful for increasing myoblast differentiation in a subject suffering from cDM1, said method comprising determining the level and/or activity of (i) PGE 2 , (ii) mPGES-1, or (iii) both (i) and (ii), in a myoblast comprising (i) PGE 2 , (ii) mPGES-1, (iii) both (i) and (ii), and/or PGE 2 biosynthetic activity; wherein a decrease in the level and/or activity in the presence relative to the absence of said test compound is indicative that said test compound is useful for increasing myoblast differentiation in the subject suffering from cDM1, and wherein said test compound does not significantly modulate PGF 2 -alpha levels and/or activity.